Bioeasy released its performance for the first three quarters, with a net profit attributable to the parent company of 18.023 million yuan, an increase of 362.49%

Bioeasy released its third-quarter report for 2025, with operating revenue of 186 million yuan in the first three quarters, a year-on-year increase of 17.45%. The net profit attributable to the parent company was 18.023 million yuan, an increase of 362.49%; the net profit excluding non-recurring gains and losses was 3.7285 million yuan, an increase of 137.78%. The basic earnings per share were 0.0449 yuan

Bioeasy's controlling shareholder and its concerted parties plan to reduce their holdings by no more than 3%

Bioeasy's controlling shareholder, Bioeasy Venture Capital, and its concerted parties plan to reduce their holdings by no more than 3% through centralized bidding or block trading within the three months from November 3, 2025, to February 2, 2026

Shenzhen Bioeasy Biotechnology Says Key Shareholders Plan To Unload 2.99% Stake In Three Months

Shenzhen Bioeasy Biotechnology Co Ltd :SAYS KEY SHAREHOLDERS PLAN TO UNLOAD 2.99% STAKE IN THREE MONTHS

Bioeasy: Net profit of 2.3395 million yuan in the first half of 2025, turning a profit from a loss year-on-year

Bioeasy announced that its operating revenue in the first half of 2025 was 109 million yuan, a year-on-year increase of 5.44%. The net profit attributable to shareholders of the listed company was 2.3395 million yuan, compared to a loss of 1.5595 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves

Pharmaceutical and medical stocks continue to strengthen, with FENGYUAN PHARMACEUTICAL hitting the limit up, Hengrui Pharma rising over 7%, and Haisco, BIOCAUSE HEILEN PHARMA, Yatai pharm, and Yirui Biologics also following suit